Skip to main content
Pulike Biological Engineering,Inc. logo

Pulike Biological Engineering,Inc. — Investor Relations & Filings

Ticker · 603566 ISIN · CNE1000025N0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,080 across all filing types
Latest filing 2017-12-07 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 603566

About Pulike Biological Engineering,Inc.

http://en.pulike.com.cn/

Pulike Biological Engineering, Inc. specializes in the research, development, and production of veterinary biological products and pharmaceutical preparations. The company focuses on animal disease prevention through the manufacture of high-end vaccines, diagnostic reagents, and veterinary medicines. Its product range primarily serves the swine and poultry sectors, featuring advanced biologicals such as genetically engineered vaccines and synthetic peptide products. Pulike maintains a strong emphasis on technological innovation, utilizing national-level research platforms to develop solutions for complex animal health challenges. The company’s core activities encompass the entire value chain from basic biotechnology research to the commercialization of veterinary health solutions, aiming to improve livestock productivity and biosecurity.

Recent filings

Filing Released Lang Actions
关于对暂时闲置募集资金和自有资金进行现金管理的实施公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding the implementation of cash management using temporarily idle raised funds and own funds. It details the purchase of various bank wealth management products, their amounts, expected returns, risk ratings, and maturity dates. The document also describes risk control measures and the impact on company operations. It references a prior shareholders' meeting resolution approving the cash management plan. The document is a formal public disclosure about the company's financing and investment activities related to cash management of idle funds, not a full financial report, earnings release, or audit report. It is not a report publication announcement since it contains substantive details about the transactions and risk controls. The content fits best under Capital/Financing Update (CAP) as it updates on the company's use of funds and financing activities through cash management products.
2017-12-07 Chinese
关于收到政府补助的公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (659 characters) from a company about receiving government subsidies. It details the amounts, sources, and accounting treatment of the subsidies. There is no financial statement or comprehensive report included, nor is it a certification or regulatory compliance document. It is an update on financing-related activity (government grants) impacting the company's income. Given the content and length, this fits best under Capital/Financing Update (CAP) rather than a full financial report or regulatory filing.
2017-10-31 Chinese
关于获得新兽药注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of a new veterinary drug registration certificate from the Ministry of Agriculture. It details the product information, development background, market context, and future procedural steps. There are no financial statements, earnings data, or management discussion of financial results. The document is an official announcement of a regulatory approval event rather than a financial report or management update. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is a regulatory announcement about a new product approval, which aligns best with Regulatory Filings (RNS) as a general category for miscellaneous regulatory announcements that do not fit other specific categories.
2017-10-25 Chinese
关于对暂时闲置募集资金和自有资金进行现金管理的实施公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 普莱柯生物工程股份有限公司 regarding the implementation of cash management for temporarily idle raised funds and own funds. It details the company's purchase of various bank financial products, including amounts, expected returns, and risk ratings. The document references a prior shareholder meeting resolution approving the cash management plan and provides detailed tables of financial products purchased, their terms, and risk control measures. There is no indication that this is a full financial report, audit report, or earnings release. Instead, it is a regulatory announcement about the company's capital management activities, specifically the use of idle funds for cash management products. The document is about financing activities but does not announce new fundraising or capital structure changes; rather, it reports on the use of existing funds for cash management. This fits best under the category of Capital/Financing Update (CAP). The document length is sufficient and contains substantive details about the cash management implementation, not just a brief notice or report publication announcement. Therefore, the classification is CAP with high confidence.
2017-10-20 Chinese
2017年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2017 年第三季度报告" which translates to "2017 Third Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and management commentary for the third quarter of 2017. The report includes actual financial figures for the period July to September 2017 and year-to-date figures for January to September 2017. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. The content and structure align with an Interim / Quarterly Report, which provides comprehensive financial information for a period shorter than a full fiscal year. Therefore, the appropriate classification is Interim / Quarterly Report (IR). 9M 2017
2017-10-16 Chinese
关于媒体报道的澄清公告
Regulatory Filings Classification · 95% confidence The document is a clarification announcement by the company regarding media reports about a new veterinary vaccine product. It explains the current status of the product's regulatory approval process and warns about potential risks. There is no financial data, no report attached or referenced as published, and no mention of a meeting or voting results. The document is a regulatory announcement clarifying information to investors and the public, fitting best under Regulatory Filings (RNS). The document length is short (1409 characters), and it is not a report itself but a clarification announcement.
2017-09-13 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.